- Home
- SST vs NSPR Comparison
SST vs NSPR Comparison
Compare SST & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- NSPR
- Stock Information
- Founded
- SST 2013
- NSPR 2005
- Country
- SST United States
- NSPR Israel
- Employees
- SST N/A
- NSPR N/A
- Industry
- SST Diversified Commercial Services
- NSPR Medical/Dental Instruments
- Sector
- SST Consumer Discretionary
- NSPR Health Care
- Exchange
- SST Nasdaq
- NSPR Nasdaq
- Market Cap
- SST 67.8M
- NSPR 63.0M
- IPO Year
- SST N/A
- NSPR N/A
- Fundamental
- Price
- SST $0.93
- NSPR $2.93
- Analyst Decision
- SST Hold
- NSPR Strong Buy
- Analyst Count
- SST 1
- NSPR 2
- Target Price
- SST $2.00
- NSPR $4.75
- AVG Volume (30 Days)
- SST 93.0K
- NSPR 78.6K
- Earning Date
- SST 11-07-2024
- NSPR 11-12-2024
- Dividend Yield
- SST N/A
- NSPR N/A
- EPS Growth
- SST N/A
- NSPR N/A
- EPS
- SST N/A
- NSPR N/A
- Revenue
- SST $364,450,000.00
- NSPR $6,821,000.00
- Revenue This Year
- SST N/A
- NSPR $13.31
- Revenue Next Year
- SST $15.56
- NSPR $52.91
- P/E Ratio
- SST N/A
- NSPR N/A
- Revenue Growth
- SST N/A
- NSPR 24.70
- 52 Week Low
- SST $0.82
- NSPR $1.81
- 52 Week High
- SST $3.02
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- SST 43.80
- NSPR 52.69
- Support Level
- SST $0.82
- NSPR $2.78
- Resistance Level
- SST $1.08
- NSPR $3.15
- Average True Range (ATR)
- SST 0.08
- NSPR 0.22
- MACD
- SST -0.00
- NSPR -0.03
- Stochastic Oscillator
- SST 40.38
- NSPR 47.58
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.